Participants who have finished first‑line chemotherapy and are either in complete remission (no detectable cancer) or have stable disease are randomly assigned to one of the two groups. They take the study medication daily for a defined period while regular check‑ups, scans, and questionnaires about quality of life are performed. The study follows each participant for several years to record any return of cancer, new health problems, or death, and the information is used to compare the two treatment approaches.

The trial will compare the effects of Clazakizumab with a placebo, which is a substance that looks like the medication but does not contain the active ingredient. The study will also use a saline solution, which is a simple saltwater solution, as part of the trial process. The purpose of the study is to determine the best dose of Clazakizumab that can effectively reduce inflammation and to assess its safety in patients with ESKD. Participants will receive the medication or placebo through an intravenous injection, which means it is given directly into a vein.

Throughout the study, researchers will monitor the participants’ health and track any changes in their condition. The study will also look at the impact of Clazakizumab on cardiovascular health, which refers to the health of the heart and blood vessels. This is important because patients with ESKD are at a higher risk of developing heart-related issues. The trial is designed to provide valuable information on how Clazakizumab can help manage inflammation and improve overall health outcomes for patients with ESKD undergoing dialysis.

The purpose of the study is to evaluate whether Orelabrutinib can delay the worsening of disability compared with placebo. Participants will receive the assigned tablet each day for several years and will attend regular clinic visits where their ability to perform everyday tasks is checked and brain scans using MRI are performed to look for new lesions. The study will track how long it takes before a confirmed increase in disability occurs and will record any safety concerns throughout the trial.

Participants will receive a series of study visits over about two years. During the visits, the assigned treatment (either the medicine or the control solution) is administered by IV infusion at set intervals, and simple tests of thinking, memory and daily functioning are performed to check for any changes. Safety checks, such as blood tests and heart monitoring, are also done regularly to ensure the treatment is well tolerated. The overall design of the trial keeps both the participants and the study staff unaware of which treatment is being given, to provide an unbiased comparison.

The goal of the trial is to find out whether adding Venetoclax to the standard three‑drug mix can improve overall survival, which means living longer after the treatment starts.

In this phase 3 study, children are placed by chance into one of two groups: one group receives the three standard drugs, and the other group receives the same three drugs plus the oral Venetoclax. Treatment is given in cycles over several weeks, and the children are checked regularly to see how they are doing and to record any side effects. The study follows each participant for a period of time to see how long they live and how they feel.

The purpose of the study is to evaluate how well the VLA15 vaccine works in preventing Lyme disease, as well as to assess its safety and how well it is tolerated by participants. The study will also look at the immune response generated by the vaccine, which is the body’s way of defending itself against infections. Participants in the study will receive a series of injections over a period of time and will be monitored for any reactions or side effects. The study will include people aged 5 years and older who live in areas where Lyme disease is common.

Throughout the study, participants will have regular check-ups to monitor their health and any potential side effects from the vaccine. The study aims to ensure that the vaccine is safe and effective for people of different ages, including children and adults. By participating in this study, researchers hope to gather important information that could lead to a new way to prevent Lyme disease in the future.

After completing an earlier trial, participants may stay in the study and keep taking the medicine each day. They will visit the clinic at regular intervals where doctors will check their health, run blood tests, and ask them to fill out several questionnaires. These include a movement assessment called MDS-UPDRS, a short thinking test known as MoCA, a severity rating questionnaire (CISI-PD), a quality‑of‑life survey (PDQ-8), an anxiety and depression screen (HAD), and a questionnaire about other symptoms (NMSQ). Any side effects or abnormal lab results will be recorded, and the safety information will be compared with data from the earlier study’s active and placebo groups.

The main aim is to see how the level of a protein called neurofilament light chain in the cerebral spinal fluid changes over time when patients switch from Rituximab to Tolebrutinib compared with staying on Rituximab. Neurofilament light chain is a substance that can rise when nerve fibers are damaged, so measuring it helps understand disease activity.

Participants will be assigned to either continue receiving Rituximab or start taking Tolebrutinib, and they will be followed for up to two years. During this period, regular clinic visits will include blood draws, occasional spinal fluid collection, and standard brain scans to monitor any changes. The study does not involve any experimental procedures beyond the approved medications and routine testing.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The study is designed as a split-body study, which means that different treatments will be applied to different areas of the body on the same person. Before starting the maintenance treatment with the creams, patients will first receive treatment with a corticosteroid cream, which is a medication that reduces inflammation, for about four weeks to clear the skin lesions. Corticosteroids are commonly used to treat skin inflammation and help calm down active eczema flare-ups. Once the skin has cleared, the maintenance phase begins, where one moisturizing cream will be applied to one study area on the body, another cream or no treatment will be applied to another area, and this will continue for up to 90 days or until the eczema comes back.

During the study, the time it takes for the eczema to return on each treated area will be measured, which is the main focus of the research. Other aspects that will be looked at include how itching changes over time in the different areas and whether any unwanted effects occur during the treatment period. Patients will report when they notice their eczema returning and how much itching they experience using a rating scale.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of this research is to determine which medication provides better and safer conditions for placing the breathing tube in adult patients who need tracheal intubation during surgery. The study will look at how well each medication works and any possible side effects that may occur during or after the procedure.

During the study, patients will receive either remifentanil or rocuronium before the breathing tube is inserted. Doctors will monitor patients for any complications that might occur within 24 hours after the procedure, including effects on breathing, heart function, or discomfort in the throat. The medication doses are carefully calculated based on each patient’s weight, with remifentanil given at up to 4 micrograms per kilogram and rocuronium at up to 0.6 milligrams per kilogram.

The main goal is to assess the long‑term safety and tolerability of the medicine, meaning researchers will watch for any side effects or problems over an extended period. After the initial treatment period, participants will continue to attend regular visits where doctors will ask about health changes, perform a simple nasal examination, and may take a small blood sample to check drug levels. The study also records whether participants need additional treatments such as a short course of a systemic corticosteroid (a pill that reduces inflammation throughout the body) or sinus surgery.

The purpose of the study is to evaluate the safety and effectiveness of these medications in children. Participants in the study will receive either Venetoclax or Ruxolitinib, or a combination of both, in the form of oral tablets or suspensions. The study will be conducted in two phases. The first phase will focus on determining the safest dose of the medications, while the second phase will assess how well the medications work in treating the cancers. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual drugs.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to observe any changes in their condition. The study aims to provide valuable information on the potential benefits of Venetoclax and Ruxolitinib for children with these challenging types of blood cancers. The study is expected to continue until 2031, with recruitment starting in 2024.

The purpose of this study is to see whether Tozorakimab can reduce the number of times COPD symptoms suddenly get worse, which are called exacerbations. These exacerbations are episodes when breathing problems become more severe than usual and may require additional treatment or even hospitalization. The study will compare two different amounts of Tozorakimab given as an injection under the skin to placebo, which will be added to the standard medications that participants are already taking for their COPD.

The study will last for about 52 weeks. During this time, participants will receive regular injections of either Tozorakimab or placebo, and doctors will monitor how often their COPD symptoms worsen and how severe these episodes are. The study focuses on people who have had at least two moderate episodes or one severe episode of worsening COPD symptoms in the past year, who are former smokers, and who continue to have symptoms despite using their regular COPD medications.

Participants in the study will receive injections of Botulinumtoxin A in specific jaw muscles, namely the masseter and temporal muscles, which are involved in chewing and jaw movement. The study will observe changes in pain levels and assess if different doses of the treatment have varying effects on pain relief. Additionally, the study will look at how the treatment impacts the quality of life, jaw function, and any psychosocial changes in participants.

The study will be conducted over a period, with participants being monitored for changes in their condition. The primary focus is on how pain levels change and whether the dose of Botulinumtoxin A matters for pain relief. Secondary observations will include improvements in quality of life and jaw function, as well as any psychosocial changes experienced by the participants. The study is expected to provide valuable insights into the treatment of myogenous TMD, which is a type of TMD caused by muscle issues.

The purpose of this study is to determine if remibrutinib is more effective than teriflunomide in reducing the frequency of relapses in people with relapsing forms of MS. Participants in the study will be randomly assigned to receive either remibrutinib, teriflunomide, or a placebo, which is a substance with no active medication. The study will begin with a period where participants receive either remibrutinib or teriflunomide, followed by an extended treatment phase where all participants will receive remibrutinib. This approach helps researchers understand the long-term effects of remibrutinib on MS.

Throughout the study, participants will take the medications orally, and their health will be monitored regularly to assess the impact of the treatments. The study aims to provide valuable information on how well remibrutinib works compared to teriflunomide and to ensure the safety of participants. By participating in this study, researchers hope to find a more effective treatment option for those living with relapsing MS.

Participants are divided into two groups based on their blood test results. For those who do not have detectable tumor DNA in their blood, the study compares a 6-month course of capecitabine alone to a 3-month course of oxaliplatin combined with capecitabine. For those who do have detectable tumor DNA, the study compares a 6-month course of fluorouracil, irinotecan, oxaliplatin, and calcium folinate to a 6-month course of fluorouracil, oxaliplatin, and calcium folinate. Calcium folinate is a substance used to help the other medications work more effectively.

During the study, the effectiveness of these treatments is monitored by looking at disease-free survival, which is the length of time a patient lives without any signs or symptoms of the cancer returning. The study also tracks overall survival and any side effects caused by the medications, such as neurotoxicity, which is damage to the nerves that can cause issues like tingling or numbness. The course of the study involves receiving the assigned medication through pills or an intravenous infusion, which is a method of delivering medicine directly into a vein through a tube.

The study compares different treatment approaches. Some participants will receive only the talk therapy, while others will receive the therapy combined with degarelix or a placebo. This research looks at how these different combinations affect behaviors and symptoms over time. Participants will be monitored for a period of time to observe changes in their behavior and physical health.

Participants in this study must have been diagnosed with fibromyalgia within the past two years and must have significant pain levels. They must also have specific antibodies in their blood that are associated with fibromyalgia. These antibodies are proteins made by the immune system that may be causing some of the pain symptoms. The study will measure how much pain decreases sixteen weeks after participants receive the rituximab treatment. Rituximab will be given through a tube inserted into a vein, which is called an infusion. The treatment period will last for one day, and participants will be followed for sixteen weeks after receiving the medicine.

During the study, researchers will measure pain levels using a scale where participants mark how much pain they feel. They will also use questionnaires to understand how fibromyalgia affects daily life and whether participants feel their condition has improved. The study will also look at changes in the antibodies in the blood to see if there is a connection between these antibodies and pain levels. The entire study is expected to run from early 2026 to early 2027.

The treatment period will last up to 10 days, with participants receiving a daily dose of up to 200 milligrams of the medication. The total amount of medication given over the treatment period will not exceed 1100 milligrams. During the study, various tests and assessments will be performed at different time points, including blood samples, thinking and memory tests, questionnaires about fatigue and quality of life, and neurological examinations. Some participants may also provide samples of cerebrospinal fluid, which is the liquid surrounding the brain and spinal cord, as well as urine and saliva samples.

Participants will be followed for up to one year after starting treatment. During this time, they will undergo cognitive testing to assess memory, learning, attention, and thinking skills at weeks 12, 26, and 52. The study will also measure fatigue levels, pain scores, overall health status, and various biological markers in blood and other body fluids. Additional tests will examine the presence of the virus, antibody responses, and other factors that might influence how well the treatment works. The study will compare results between those receiving remdesivir and those receiving placebo to determine if the medication is effective in treating this infection.

Participants in this study will be randomly assigned to receive either prednisolone or placebo for 10 days. The study is designed so that neither the participants nor the doctors will know who is receiving which treatment. To make the treatments look the same, the prednisolone tablets will be placed inside capsules. During the study, participants will be asked to complete questionnaires that measure dizziness and balance symptoms, as well as how these symptoms affect daily life and overall quality of life. These questionnaires will be completed at different times: 2 weeks, 6 weeks, 3 months, and 12 months after starting the treatment.

The study will also include tests to measure how well the balance system is working. These include a video test that measures eye movements when the head is moved quickly, a timed walking test, measurements of body movement while standing and walking, and a test of standing on a foam pad. Some of these tests will be done at the beginning of the study and again at 6 weeks to see if there are any changes. The main focus will be on comparing the dizziness symptom scores between the two groups at 6 weeks after treatment starts. The study will also look at healthcare use and time off work to understand the broader impact of the treatment.

The purpose of the study is to find out if adding Saruparib to the standard treatment of radiotherapy and androgen deprivation therapy can help men with this type of prostate cancer live longer without the cancer spreading to distant parts of the body compared to placebo. The study will measure how long participants remain free of distant spread of cancer, which is called metastases-free survival, and will also look at overall survival and other measures of how well the treatment works. During the study, participants will receive the study medication in tablet form taken by mouth, and they will need to have various scans including computed tomography or magnetic resonance imaging, bone scans, and prostate-specific membrane antigen-positron emission tomography scans to check for any signs of cancer spread.

Participants will be randomly assigned to receive either the active study medication or placebo in addition to their standard treatment, and neither the participants nor their doctors will know which treatment they are receiving during the study. The study requires tissue samples from the prostate cancer to confirm the presence of the BRCA gene mutation before enrollment. Throughout the study, participants will be monitored for how the treatment affects their cancer, their overall health, and their quality of life through questionnaires about symptoms and daily functioning. Blood samples will also be collected to measure the levels of the study medication in the body and to understand how it works.

During the study, participants will receive the medication or placebo as an injection under the skin using a device. The treatment will be given over a period of 48 weeks, with the total amount of medication not exceeding 600 milligrams. Participants will need to continue taking their regular asthma medications during the study, which may include inhaled corticosteroids and other controller medications such as long-acting bronchodilators, leukotriene modifiers, or other medicines prescribed by their doctor. To be part of this study, participants must have been diagnosed with asthma for at least 12 months and must have certain characteristics such as elevated levels of a type of white blood cell called eosinophils in their blood, which indicates a specific type of asthma inflammation. They must also have experienced at least one asthma worsening episode in the past year that required treatment with systemic corticosteroids, an emergency room visit, or hospitalization.

Throughout the study, doctors will monitor participants closely by checking various measurements including lung function tests such as FEV1, which measures how much air a person can forcefully exhale in one second, and FeNO, which measures the level of nitric oxide in exhaled breath as a marker of airway inflammation. Blood tests will be done to measure eosinophil counts and to check for any antibodies the body might make against the study medication. Participants will also complete questionnaires about their asthma symptoms, how well their asthma is controlled, and their quality of life. The study will track any side effects, changes in vital signs, laboratory test results, and heart rhythm measurements through electrocardiogram. The entire study participation will last approximately 60 weeks, which includes the treatment period and a follow-up period after the last dose of medication.